JMP Securities lowered the firm’s price target on Enanta (ENTA) to $21 from $22 and keeps an Outperform rating on the shares. Enanta ended FY24 with cash of $248M and guiding to runway into FY27, and remains on track for results from the pediatric treatment Phase 2 trial of oral RSV N-protein inhibitor zelicapavir next month, the analyst tells investors in a research note. The Phase 2 in high-risk adults is expected to complete enrollment within the North American RSV season, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue